Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2022

BioPharm International

  • BioPharm International, February 2022
  • Volume 35
  • Issue 2
  • Pages: 40

Single-Stage Clarification

The 3M Harvest RC clarifier condenses three process steps into a single-stage purification of recombinant protein therapeutics.

The 3M Harvest RC clarifier from 3M Health Care uses a proprietary fibrous chromatography media to condense three process steps into a single-stage purification of recombinant protein therapeutics.

The clarifier provides monoclonal antibody recovery of more than 95% and can be used with cultures with different cell densities, high-packed cell volumes, and cell culture characteristics. The quaternary ammonium functionalized polypropylene fiber, and 0.2 µm PES membrane, provides scalable clarification from discovery to commercial manufacturing scale.

The clarifier introduces chromatographic separation earlier in the process to remove soluble impurities, resulting in cleaner effluent, the company reports.

Articles in this issue


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.